The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Open accessAbstract
BACKGROUND: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial. METHODS: We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600-mutant metastatic melanoma to investigate the efficacy of vemurafenib with respect to overall response rate (percentage of treated patients with a tumor response), duration of response, and overall survival. The primary end point was the overall response rate as ascertained by the independent review committee; overall survival was a secondary end point. RESULTS: A total of 132 patients had a median follow-up of 12.9 months (range, 0.6 to 20.1). The confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), the median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and the median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Primary progression was observed in only 14% of patients. Some patients had a response after receiving vemurafenib for more than 6 months. The median overall survival was 15.9 months (95% CI, 11.6 to 18.3). The most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopecia. Cutaneous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients. CONCLUSIONS: Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma. In this study with a long follow-up, the median overall survival was approximately 16 months. (Funded by Hoffmann-La Roche; ClinicalTrials.gov number, NCT00949702.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, BRAF inhibitors led to a monotherapy response rate of >50% in BRAFV600E melanoma and ~30% in BRAFV600E NSCLC, but only ~5% in BRAFV600E colorectal cancer, likely due to the variable robustness of adaptive feedback networks in each tumor type (45–49).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Self-citationAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043
Cited by
Sorted by citations
Items 901–1,000 of 1,003
Schmitt, M., Sinnberg, T. W., Nalpas, N., Maaß, A., Schittek, B., & Maček, B. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001302 · Cited by 28
Hu, M., Yu, Z., Mei, P., Li, J., Luo, D., Zhang, H., Zhou, M., Liang, F., & Chen, R. (2020) · Aging · doi:10.18632/aging.102606 · Cited by 28
Self-citationTiago, M., Capparelli, C., Erkes, D. A., Purwin, T. J., Heilman, S. A., Berger, A. C., Davies, M. A., & Aplin, A. E. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0724-y · Cited by 30
Song, Z., Lin, J., Sun, Z., Ni, J., & Yang, S. (2015) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2015.03.020 · Cited by 28
Goldinger, S. M., Rinderknecht, J. D., Dummer, R., Kuhn, F. P., Yang, K., Lee, L., Ayala, R. C., Racha, J. K., Geng, W., Moore, D., et al. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.113 · Cited by 28
Self-citationPrimary Cutaneous Melanoma—Management in 2024
Dixon, A. J., Sladden, M. J., Zouboulis, C. C., Popescu, C. M., Nirenberg, A., Steinman, H. K., Longo, C., Dixon, Z. L., & Thomas, J. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061607 · Cited by 29
Quast, S.-A., Berger, A., Plötz, M., & Eberle, J. (2013) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2013.11.003 · Cited by 27
BRAF mutation in hairy cell leukemia
Ahmadzadeh, A., Shahrabi, S., Jaseb, K., Norozi, F., Shahjahani, M., Vosoughi, T., Hajizamani, S., & Saki, N. (2014) · Oncology Reviews · doi:10.4081/oncol.2014.253 · Cited by 27
Adachi, E., Sakai, K., Nishiuchi, T., Imamura, R., Sato, H., & Matsumoto, K. (2016) · Oncotarget · doi:10.18632/oncotarget.12221 · Cited by 27
Targeted therapy for malignant melanoma
Lorentzen, H. F. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.05.010 · Cited by 27
Mekkawy, A. I., Naguib, Y. W., Alhaj-Suliman, S. O., Wafa, E. I., Ebeid, K., Acri, T. M., & Salem, A. K. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120876 · Cited by 27
Forsberg, E. M. V., Riise, R. E., Saellström, S., Karlsson, J. W., Alsén, S., Bucher, V., Hemminki, A., Bagge, R. O., Ny, L., Nilsson, L. M., et al. (2023) · Cancers · doi:10.3390/cancers15030648 · Cited by 27
Circulating Melanoma Cells as a Predictive Biomarker
Karakousis, G. C., Yang, R., & Xu, X. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.34 · Cited by 27
Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest
Acquavella, N., Clever, D. C., Yu, Z., Parker, M. R., Palmer, D. C., Xi, L., Pflicke, H., Ji, Y., Gros, A., Hanada, K., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0122 · Cited by 27
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications
Grossmann, K. F., & Margolin, K. A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015572284 · Cited by 27
Mackiewicz, A. A., Mackiewicz, J., Wysocki, P. J., Wiznerowicz, M., Kapcińska, M., Łaciak, M., Rose‐John, S., Iżycki, D., Burzykowski, T., & Karczewska-Dzionk, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.684753 · Cited by 27
Shelledy, L., & Danielle Roman, P. (2015) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2015.6.4.6 · Cited by 27
Molecular genetic and immunotherapeutic targets in metastatic melanoma
Melis, C., Rogiers, A., Bechter, O. E., & van den Oord, J. J. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2113-3 · Cited by 28
Gene Therapy for Advanced Melanoma: Selective Targeting and Therapeutic Nucleic Acids
Viola, J. R., Rafael, D. F. D. S., Wagner, E., Besch, R., & Ogris, M. (2013) · Journal of Drug Delivery · doi:10.1155/2013/897348 · Cited by 27
BRAF V600E Mutation and Papillary Thyroid Cancer: Chicken or Egg?
Xing, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2201 · Cited by 27
BRAF V600E-dependent role of autophagy in uveal melanoma
Zhao, Y., Wang, W., Min, I., Wyrwas, B., Moore, M., Zarnegar, R., & Fahey, T. J. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2317-y · Cited by 26
BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma
Richman, J., Martín-Liberal, J., Diem, S., & Larkin, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1044971 · Cited by 27
Radiosensibilisation induite par le vémurafénib
Ducassou, A., David, I., Delannes, M., Chevreau, C., & Sibaud, V. (2013) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2013.04.004 · Cited by 26
Ganzenmueller, T., Hage, E., Yakushko, Y., Kluba, J., Woltemate, S., Schacht, V., Schulz, T. F., & Gutzmer, R. (2013) · Experimental Dermatology · doi:10.1111/exd.12249 · Cited by 26
Development of gadolinium based nanoparticles having an affinity towards melanin
Morlieras, J., Chezal, J., Miot‐Noirault, E., Roux, A., Heinrich, L., Cohen, R., Tarrit, S., Truillet, C., Mignot, A., Hachani, R., et al. (2012) · Nanoscale · doi:10.1039/c2nr33457g · Cited by 26
Precision medicine in oncology drug development: a pharma perspective
Hollingsworth, S. J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.10.005 · Cited by 26
Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature
Vázquez‐Osorio, I., Rojas, M. D. S., García‐Rodiño, S., Peñaranda, J. M. S., Aliste, C., & Vázquez-Veiga, H. A. (2016) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000528 · Cited by 26
Integrating first-line treatment options into clinical practice
Dummer, R., Schadendorf, D., Ascierto, P. A., Larkin, J., Lebbé, C., & Hauschild, A. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000200 · Cited by 26
MAPK pathway inhibition in melanoma: resistance three ways
Wellbrock, C. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140020 · Cited by 29
Medical management of malignant melanoma
Atkinson, V. G. (2015) · Australian Prescriber · doi:10.18773/austprescr.2015.028 · Cited by 26
Novel Targeted Therapies for Metastatic Melanoma
Iams, W. T., Sosman, J. A., & Chandra, S. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000242 · Cited by 28
Self-citationYang, H., Kircher, D. A., Kim, K., Grossmann, A. H., VanBrocklin, M. W., Holmen, S. L., & Robinson, J. P. (2017) · Oncogene · doi:10.1038/onc.2016.526 · Cited by 27
Self-citationHeme oxygenase 1 facilitates cell proliferation via the B-Raf-ERK signaling pathway in melanoma
Liu, L., Wu, Y. L., Bian, C., Nisar, M. F., Wang, M., Hu, X., Diao, Q., Nian, W., Wang, E., Xu, W., et al. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-018-0313-3 · Cited by 26
Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis
Ito, T., Kaku‐Ito, Y., Murata, M., Ichiki, T., Kuma, Y., Tanaka, Y., Taketoshi, I. D. E., Ohno, F., WADA-OHNO, M., Yamada, Y., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246191 · Cited by 26
Melanoma Metabolism: Cell Survival and Resistance to Therapy
Luís, R., Brito, C., & Pojo, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34025-4_11 · Cited by 26
Grzywa, T. M., Klicka, K., Paskal, W., Dudkiewicz-Garbicz, J., Wejman, J., Pyźlak, M., & Wlodarski, P. K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234707 · Cited by 26
Gkiala, A., & Palioura, S. (2020) · Clinical ophthalmology · doi:10.2147/opth.s271569 · Cited by 27
Abdel-Rahman, O. M., Elhalawani, H. M., & Ahmed, H. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1438-0 · Cited by 26
BRAF , NRAS and KIT sequencing analysis of spindle cell melanoma
Kim, J., Lazar, A. J., Davies, M. A., Homsi, J., Papadopoulos, N. E., Hwu, W., Bedikian, A. Y., Woodman, S. E., Patel, S. P., Hwu, P., et al. (2012) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2012.01950.x · Cited by 26
Self-citationThe Dark Side of Cyclophosphamide: Cyclophosphamide-Mediated Ablation of Regulatory T Cells
Becker, J. C., & Schrama, D. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.67 · Cited by 26
A new generation of companion diagnostics: cobasBRAF, KRASandEGFRmutation detection tests
Angulo, B., López‐Ríos, F., & de Castro, D. G. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.910120 · Cited by 26
Leptomeningeal metastasis from solid tumors: a single center experience in Chinese patients
Du, C., Hong, R., Shi, Y., Yu, X., & Wang, J. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1228-x · Cited by 26
A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations
Ryslik, G., Cheng, Y., Cheung, K.-H., Modis, Y., & Zhao, H. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-86 · Cited by 27
A computationally engineered RAS rheostat reveals RAS–ERK signaling dynamics
Rose, J. C., Huang, P., Camp, N. D., Ye, J., Leidal, A. M., Goreshnik, I., Trevillian, B. M., Dickinson, M. S., Cunningham‐Bryant, D., Debnath, J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2244 · Cited by 26
Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging
Mikula, H., Stapleton, S., Köhler, R. H., Vinegoni, C., & Weissleder, R. (2017) · Theranostics · doi:10.7150/thno.18238 · Cited by 26
Izar, B., Sharfman, W. H., Hodi, F. S., Lawrence, D. P., Flaherty, K. T., Amaravadi, R. K., Kim, K. B., Puzanov, I. J., Sosman, J. A., Dummer, R., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1140 · Cited by 26
Self-citationVemurafenib Limits Influenza A Virus Propagation by Targeting Multiple Signaling Pathways
Holzberg, M., Boergeling, Y., Schräder, T., Ludwig, S., & Ehrhardt, C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02426 · Cited by 26
Huestis, M. P., Cruz, D. D., DiPasquale, A. G., Durk, M. R., Eigenbrot, C. W., Gibbons, P., Gobbi, A., Hunsaker, T., La, H., Leung, D. H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02085 · Cited by 26
Hou, S., Zhao, L., Shen, Q., Yu, J., Ng, C., Kong, X., Wu, D., Song, M., Shi, X., Xu, X., et al. (2013) · Angewandte Chemie · doi:10.1002/ange.201208452 · Cited by 27
Self-citationChen, C. Y., & Tang, H. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s80150 · Cited by 26
HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E
Chang, X., Zhang, T., Wang, Q., Rathore, M. G., Reddy, K., Chen, H., Shin, S. H., Ma, W.-Y., Bode, A. M., & Dong, Z. (2020) · Theranostics · doi:10.7150/thno.44342 · Cited by 26
Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases
Khaled, M. L., Tarhini, A. A., Forsyth, P. A., Smalley, I., & Piña, Y. (2023) · Cancers · doi:10.3390/cancers15061884 · Cited by 25
Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma
Borbényi-Galambos, K., Erdélyi, K., Ditrói, T., Jurányi, E. P., Szántó, N., Szatmári, R. Z., Czikora, Á., Schmidt, E. E., Garai, D., Cserepes, M., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.021 · Cited by 26
Current advances and perspectives in the treatment of advanced melanoma
Livingstone, E., Zimmer, L., Vaübel, J., & Schadendorf, D. (2012) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2012.07895.x · Cited by 26
Drug compound characterization by mass spectrometry imaging in cancer tissue
Kwon, H. J., Kim, Y., Sugihara, Y., Baldetorp, B., Welinder, C., Watanabe, K., Nishimura, T., Malm, J., Török, S., Döme, B., et al. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0627-2 · Cited by 25
Prognostic and predictive biomarkers in melanoma: an update
Foth, M., Wouters, J., de Chaumont, C., Dynoodt, P., & Gallagher, W. M. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1126511 · Cited by 25
Czirbesz, K., Gorka, E., Balatoni, T., Pánczél, G., Melegh, K., Kovacs, P. L., Gézsi, A., & Liszkay, G. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0324-1 · Cited by 25
Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma
Czauderna, C., Kirstein, M. M., Tews, H. C., Vogel, A., & Marquardt, J. U. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132803 · Cited by 25
Ekebergh, A., Lingblom, C., Sandin, P., Wennerås, C., & Mårtensson, J. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob02694b · Cited by 25
Bohn, O. L., Hsu, K. C., Hyman, D. M., Pignataro, D. S., Giralt, S., & Teruya‐Feldstein, J. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.12.003 · Cited by 25
Bhaskaran, S., Dileep, K. V., Deepa, S. S., Sadasivan, C., Klausner, M., Krishnegowda, N. K., TEKMAL, R. R., VandeBerg, J. L., & Nair, H. B. B. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0965 · Cited by 25
Andersson, T., Eriksson, H., Hansson, J., Månsson‐Brahme, E., Dickman, P. W., Eloranta, S., Lambe, M. P., & Lambert, P. C. (2014) · Cancer Epidemiology · doi:10.1016/j.canep.2013.12.006 · Cited by 25
Hong, D. S., Kurzrock, R., Falchook, G. S., Andresen, C., Kwak, J., Ren, M., Xu, L. T., George, G. C., Kim, K. B., Nguyen, L. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5756 · Cited by 25
Self-citationKeating, G. M. (2016) · Drugs · doi:10.1007/s40265-016-0562-7 · Cited by 26
An Agonistic Antibody to EPHA2 Exhibits Antitumor Effects on Human Melanoma Cells
Sakamoto, A., Kato, K., Hasegawa, T., & Ikeda, S. (2018) · Anticancer Research · doi:10.21873/anticanres.12592 · Cited by 25
Future Roadmaps for Precision Medicine Applied to Diabetes: Rising to the Challenge of Heterogeneity
Bowman, P., Flanagan, S. E., & Hattersley, A. T. (2018) · Journal of Diabetes Research · doi:10.1155/2018/3061620 · Cited by 26
Paudel, B. B., Lewis, J. E., Hardeman, K. N., Hayford, C. E., Robbins, C. T., Stauffer, P. E., Codreanu, S. G., Sherrod, S. D., MCLEAN, J. A. J., Kemp, M. L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3588 · Cited by 25
Recent advances in the treatment of melanoma with BRAF and MEK inhibitors.
Muñoz‐Couselo, E., García, J. S., Pérez-García, J. M., Cebrian, V. O., & Cortés, J. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.05.13 · Cited by 24
Major therapeutic developments and current challenges in advanced melanoma
Sullivan, R. J., & Flaherty, K. T. (2014) · British Journal of Dermatology · doi:10.1111/bjd.12698 · Cited by 24
Self-citationUgurel, S., Loquai, C., Kähler, K. C., Hassel, J. C., Berking, C., Zimmer, L., Haubitz, I., Satzger, I., Müller-Brenne, T., Mikhaimer, N. C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu573 · Cited by 24
Asundi, J., Lacap, J. A., Clark, S., Nannini, M., Roth, L. A., & Polakis, P. G. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0446 · Cited by 26
Emelyanova, M., Ghukasyan, L., Abramov, I. S., Ryabaya, O. O., Степанова, Е. В., Kudryavtseva, A. V., Садритдинова, А. Ф., Dzhumakova, C., Белышева, Т. С., Суржиков, С. А., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17014 · Cited by 24
McGrail, K., Granado‐Martínez, P., Esteve‐Puig, R., García-Ortega, S., Ding, Y., Sánchez‐Redondo, S., Fábrega, B. F., Hernández‐Losa, J., Canals, F., Manzano, À., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34907-0 · Cited by 25
Treatment of acral and mucosal melanoma: Current and emerging targeted therapies
Zhang, J., Tian, H., Mao, L., & Si, L. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104221 · Cited by 24
MacLeod, A. K., McLaughlin, L. A., Henderson, C. J., & Wolf, C. R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1454 · Cited by 24
Marchant, J., Mangé, A., Larrieux, M., Costes, V., & Solassol, J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-519 · Cited by 24
Sellin, J. N., Gressot, L. V., Suki, D., Clair, E. G. S., Chern, J. J., Rhines, L. D., McCutcheon, I. E., Rao, G., & Tatsui, C. E. (2015) · Neurosurgery · doi:10.1227/neu.0000000000000790 · Cited by 24
Göppner, D., Müller, J., Krüger, S., Franke, I., Gollnick, H. P. M., & Quist, S. (2014) · Acta Dermato Venereologica · doi:10.2340/00015555-1813 · Cited by 24
Xue, G., Kohler, R. S., Tang, F., Hynx, D., Wang, Y., Orso, F., Prêtre, V., Ritschard, R., Hirschmann, P., Cron, P. D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18213 · Cited by 25
Quality‐of‐life outcomes in patients with advanced melanoma: A review of the literature
Malkhasyan, K. A., Zakharia, Y., & Milhem, M. M. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12647 · Cited by 24
Hallmeyer, S., Gonzalez, R. C., Lawson, D. H., Cranmer, L. D., Linette, G. P., Puzanov, I. J., Taback, B., Cowey, C. L., Ribas, A., Daniels, G. A., et al. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000398 · Cited by 24
Self-citationZhang, Y., Zhan, X., Peng, S., Cai, Y., Zhang, Y. S., Yu, Y., Wang, Y., Yu, Y., Wang, Y., 施桥发, et al. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.04.010 · Cited by 24
Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin
Dorasamy, M. S., Aravind, A. B., Nellore, K., & Wong, P. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.010 · Cited by 24
Detection of BRAFV600E Mutation in Melanoma Patients by Digital PCR of Circulating DNA
Burjanivová, T., Malicherová, B., Grendár, M., Minaríková, E., Dusenka, R., Váňová, B., Bobrovská, M., Péčová, T., Homola, I., Lasabová, Z., et al. (2019) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2018.0193 · Cited by 24
Modelling bistable tumour population dynamics to design effective treatment strategies
Akhmetzhanov, A. R., Kim, J. W., Sullivan, R. J., Beckman, R. A., Tamayo, P., & Yeang, C. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.05.005 · Cited by 24
Shahin, R. O., Jaafreh, S. M., & Azzam, Y. (2025) · Future Science OA · doi:10.1080/20565623.2025.2483631 · Cited by 23
Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant–Expressing Melanoma
Hartsough, E. J., Basile, K. J., & Aplin, A. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0581 · Cited by 24
Melanoma m1: diagnosis and therapy.
Rastrelli, M., Tropea, S., Pigozzo, J., Bezzon, E., Campana, L. G., Stramare, R., Alaibac, M., & Rossi, C. R. (2014) · PubMed · Cited by 23
Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition
Lau, P. K. H., Ascierto, P. A., & McArthur, G. A. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.006 · Cited by 23
Self-citationLoss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition
Ji, Z., Njauw, C.-N. J., Guhan, S. M., Kumar, R., Reddy, B. Y., Rajadurai, A., Flaherty, K. T., & Tsao, H. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.06.041 · Cited by 24
Self-citationGenomic profiling of gallbladder carcinoma: Targetable mutations and pathways involved
Mishra, S., Kumari, S., Srivastava, P., Pandey, A., Shukla, S., & Husain, N. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153806 · Cited by 23
Liu, Y., Dong, C., He, X., Shu, Y., Wu, P., & Zou, J. (2022) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps33020 · Cited by 23
Haist, M., Stege, H. M., Kuske, M., Bauer, J., Klumpp, A., Grabbe, S., & Bros, M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10097-z · Cited by 24
A twenty year perspective on melanoma therapy
Flaherty, K. T. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13125 · Cited by 23
Self-citationHatch, S. B., Swift, L. P., Caporali, S., Carter, R., Hill, E. J., MacGregor, T. P., D’Atri, S., Middleton, M. R., McHugh, P. J., & Sharma, R. A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28454 · Cited by 23
Mai, R., Zhou, S., Zhong, W., Rong, S., Cong, Z., Li, Y., Xie, Q., Chen, H., Li, X., Liu, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4375 · Cited by 23
Sale, M. J., & Cook, S. J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12220 · Cited by 23
The spectrum of clinical trials aiming at personalizing medicine.
Tourneau, C. L., Kamal, M. T., Alt, M., Verlingue, L., Servois, V., Sablin, M., Servant, N., & Paolettí, X. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.05.02 · Cited by 23
Finding chemical drugs for genetic diseases
Sun, H., Hou, T., & Zhang, H. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.013 · Cited by 23
Dillman, R. O., Barth, N. M., VanderMolen, L. A., Mahdavi, K., & McClure, S. E. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1220 · Cited by 23
Metadata
- Authors
- Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., Hersey, P., Kefford, R., Lawrence, D., Puzanov, I., Lewis, K. D., Amaravadi, R. K., Chmielowski, B., Lawrence, H. J., Shyr, Y., Ye, F., Li, J., Nolop, K. B., Lee, R. J., Joe, A. K., & Ribas, A.
- Affiliations
- Vanderbilt University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Abramson Cancer Center (US)
- University of Colorado Denver (US)
- New York University (US)
- Moffitt Cancer Center (US)
- Peter MacCallum Cancer Centre (AU)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- University of Newcastle Australia (AU)
- Melanoma Institute Australia (AU)
- Vanderbilt-Ingram Cancer Center (US)
- University of California, Los Angeles (US)
- Vanderbilt University Medical Center (US)
- Plexxikon (United States) (US)
- ORCID
- Sosman, Jeffrey A.
- Kim, Kevin B.
- Schuchter, Lynn
- Gonzalez, Rene
- Pavlick, Anna C.
- Weber, Jeffrey S.
- McArthur, Grant A.
- Hutson, Thomas E.
- Moschos, Stergios J.
- Flaherty, Keith T.
- Hersey, Peter
- Kefford, Richard
- Lawrence, Donald
- Puzanov, Igor
- Lewis, Karl D.
- Amaravadi, Ravi K.
- Chmielowski, Bartosz
- Shyr, Yu
- Ye, Fei
- Li, Jiang
- Lee, Richard J.
- Ribas, Antoni
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-02-23
- Volume
- 366
- Issue
- 8
- Pages
- 707-714
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3724515
- OpenAlex
- W2168143310
- Cited by
- 2,156
- References
- 36
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 56 · 2023: 85 · 2022: 113 · 2021: 88 · 2020: 110 · 2019: 109 · 2018: 132 · 2017: 171 · 2016: 198 · 2015: 258 · 2014: 318 · 2013: 306 · 2012: 160
- FWCI
- 133.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Figshare (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Cancer Institute (K24CA097588, P30CA076292)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, metastatic melanoma, BRAF inhibitors, overall survival, overall response rate, duration of response, progression-free survival, cutaneous squamous cell carcinoma, keratoacanthoma, adverse events
- MeSH terms
- Vemurafenib, Adult, Aged, Female, Humans, Indoles, Male, Melanoma, Middle Aged, Mutation, Neoplasm Metastasis, Sulfonamides, Treatment Outcome, Disease Progression, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
